EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Normal-BMI MASLD is associated with increased mortality, cardiovascular events, cancer, and lower GLP-1 use

Isabel Casimiro, Aoi Ogawa, Rachel Haide Naraval Tacata, Eunjung Lim, Scott K Kuwada

The Journal of Clinical Endocrinology & Metabolism · 2026-10-28

DOI: 10.1210/clinem/dgag439 ↗
AbstractBibliografische Angaben

Abstract

Abstract Background Metabolic dysfunction–associated steatotic liver disease (MASLD) can occur in individuals who are not overweight or have obesity (normal-body mass index [BMI] MASLD [nbMASLD]), yet disease burden and management remain poorly characterized. We compared long-term outcomes and incretin-based therapy use between nbMASLD and overweight/obesity-associated MASLD (obMASLD) across racial and ethnic groups. Methods We conducted a retrospective, observational study using the TriNetX United States Network. Adults diagnosed with MASLD or metabolic dysfunction–associated steatohepatitis from 2005 to 2025 were classified using ethnicity-informed normal-BMI thresholds: <23 kg/m2 for Asian, <27 kg/m2 for Native Hawaiian and Pacific Islander, and <25 kg/m2 for White/others. Propensity score matching balanced demographic and clinical covariates. Outcomes were assessed using Kaplan–Meier analyses and Cox proportional hazards models with obMASLD as the reference group. Results Among 619 171 eligible patients, 51 940 matched pairs were identified. Nb-BMI MASLD was associated with higher all-cause mortality across grouped ethnic groups, with survival of 77.49% vs 83.93% in obMASLD (hazard ratio, 1.735; confidence interval, 1.653-1.822). Ethnicity-specific risks included higher myocardial infarction risk in White and Black patients, higher stroke risk in White patients, higher end-stage renal disease risk in Black patients, and increased cancers (colorectal, pancreatic and multiple myeloma) among White patients. Incretin-based therapy use was markedly lower in nbMASLD but was associated with improved survival. Conclusion Patients with nbMASLD demonstrated an increased mortality and ethnicity-specific clinical complications than obMASLD despite a more favorable metabolic profile. These findings demonstrate a potential treatment gap for nbMASLD patients and the shortcomings of BMI-based strategies to risk stratify MASLD patients.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →